Retatrutide for PCOS: Fertility and Weight

PCOS affects 10% of women of reproductive age and is responsible for up to 80% of anovulatory infertility cases. The condition creates a hormonal environment hostile to conception: insulin resistance drives excessive androgen production, which disrupts follicular development and prevents ovulation. Even when ovulation occurs, the metabolic environment of PCOS reduces egg quality, impairs endometrial receptivity, and increases miscarriage risk. Weight loss addresses all of these mechanisms, making it the most powerful single intervention for PCOS-related infertility -- and GLP-1 medications produce more weight loss than any previous non-surgical approach.

How PCOS Causes Infertility

The infertility cascade in PCOS follows a predictable pattern rooted in insulin resistance. Hyperinsulinemia stimulates ovarian theca cells to overproduce androgens. Elevated androgens disrupt normal follicular development, causing follicles to arrest before reaching ovulatory maturity (creating the characteristic "polycystic" appearance on ultrasound). Without a dominant follicle reaching maturity, ovulation does not occur (anovulation). Without ovulation, progesterone is not produced, leading to irregular or absent periods and an unprepared endometrium. And even when ovulation does occur sporadically, the metabolic environment reduces egg quality and implantation success.

Weight Loss and Ovulation Restoration

The dose-response relationship between weight loss and ovulation restoration is well-documented. Just 5% weight loss restores ovulatory cycles in approximately 30% of anovulatory PCOS patients. At 10% weight loss, approximately 50% regain regular ovulation. At 15-20% weight loss, the majority of patients resume ovulatory cycles. With 24% weight loss (as seen with retatrutide), near-complete restoration of ovulation would be expected in most patients.

Importantly, weight loss improves not just ovulation frequency but also egg quality, hormone balance, endometrial receptivity, and pregnancy maintenance -- addressing fertility at every level of the reproductive process.

Retatrutide as Preconception Strategy

The optimal approach for PCOS patients planning pregnancy involves using GLP-1 medication to achieve significant weight loss (ideally 15-25%), establishing healthy eating and exercise habits during the treatment period, discontinuing medication at least 2 months before planned conception, using the improved metabolic health window to conceive naturally or with fertility assistance, and maintaining healthy habits through pregnancy for optimal outcomes.

This "treat, stabilize, conceive" strategy maximizes the fertility benefits of weight loss while respecting medication safety requirements.

Warning: Unexpected Fertility Restoration

An important caution for PCOS patients starting weight loss treatment: weight loss can restore ovulation before you are ready to conceive. Women who have relied on their anovulatory state as de facto contraception must understand that GLP-1 treatment may rapidly restore fertility. Reliable contraception is essential during treatment. See our fertility guide for contraception recommendations during GLP-1 use.

Start Your Preconception Journey

Compounded semaglutide ($99/mo) and compounded tirzepatide ($125/mo) can begin improving insulin sensitivity and supporting weight loss now. Coordinate with your reproductive endocrinologist for optimal fertility planning.